ES2368732T3 - Agente terapéutico para el trastorno de la capacidad alimentaria en el estómago. - Google Patents

Agente terapéutico para el trastorno de la capacidad alimentaria en el estómago. Download PDF

Info

Publication number
ES2368732T3
ES2368732T3 ES03745958T ES03745958T ES2368732T3 ES 2368732 T3 ES2368732 T3 ES 2368732T3 ES 03745958 T ES03745958 T ES 03745958T ES 03745958 T ES03745958 T ES 03745958T ES 2368732 T3 ES2368732 T3 ES 2368732T3
Authority
ES
Spain
Prior art keywords
group
stomach
compound
gastric
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03745958T
Other languages
English (en)
Spanish (es)
Inventor
Yugo Matsunaga
Shigeru Ueki
Raita Higashino
Masanao Kawachi
Hiroki Kato
Shiro Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28786350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2368732(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2368732T3 publication Critical patent/ES2368732T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES03745958T 2002-04-08 2003-04-08 Agente terapéutico para el trastorno de la capacidad alimentaria en el estómago. Expired - Lifetime ES2368732T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002104894 2002-04-08
JP2002104894 2002-04-08

Publications (1)

Publication Number Publication Date
ES2368732T3 true ES2368732T3 (es) 2011-11-21

Family

ID=28786350

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03745958T Expired - Lifetime ES2368732T3 (es) 2002-04-08 2003-04-08 Agente terapéutico para el trastorno de la capacidad alimentaria en el estómago.

Country Status (14)

Country Link
US (4) US20050176788A1 (cg-RX-API-DMAC7.html)
EP (2) EP2301540A1 (cg-RX-API-DMAC7.html)
JP (2) JP5281226B2 (cg-RX-API-DMAC7.html)
KR (4) KR101423284B1 (cg-RX-API-DMAC7.html)
CN (2) CN1646123A (cg-RX-API-DMAC7.html)
AT (1) ATE522214T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003236326B2 (cg-RX-API-DMAC7.html)
CA (1) CA2481916C (cg-RX-API-DMAC7.html)
CY (1) CY1112057T1 (cg-RX-API-DMAC7.html)
DK (1) DK1493441T3 (cg-RX-API-DMAC7.html)
ES (1) ES2368732T3 (cg-RX-API-DMAC7.html)
PT (1) PT1493441E (cg-RX-API-DMAC7.html)
SI (1) SI1493441T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003084537A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447612A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 阿考替胺水合物晶型及其制备方法和用途
CN103980226A (zh) * 2014-05-10 2014-08-13 杭州新博思生物医药有限公司 盐酸阿考替胺水合物晶型及其制备方法
CN105315225A (zh) * 2014-07-07 2016-02-10 中美华世通生物医药科技（武汉）有限公司 阿考替胺的酸加成盐及其制备方法
CN104045606B (zh) * 2014-07-11 2015-09-30 杭州新博思生物医药有限公司 一锅法制备阿考替胺盐酸盐的方法
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063442C (zh) * 1995-05-18 2001-03-21 泽里新药工业株式会社 氨基噻唑衍生物、含有它们的药物组合物及其用途
JPH10212271A (ja) * 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
PT994108E (pt) * 1997-06-24 2003-09-30 Zeria Pharm Co Ltd Processo de producao de derivados de 2-hidroxibenzamida
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
NZ511117A (en) * 1998-11-23 2002-11-26 Janssen Pharmaceutica Nv Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
JP2003501427A (ja) * 1999-06-02 2003-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノアルキル置換（ベンゾジオキサン、ベンゾフランもしくはベンゾピラン）誘導体
CA2391497C (en) * 1999-11-23 2008-12-30 Janssen Pharmaceutica N.V. Use of 5ht3 agonists for relaxing the fundus
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
JP4876367B2 (ja) * 2000-09-08 2012-02-15 ゼリア新薬工業株式会社 アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤
US6986882B2 (en) * 2002-01-17 2006-01-17 Astrazeneca Ab Therapy for functional dyspepsia

Also Published As

Publication number Publication date
KR20120037035A (ko) 2012-04-18
KR101423284B1 (ko) 2014-07-24
AU2003236326B2 (en) 2008-02-28
JP5281226B2 (ja) 2013-09-04
PT1493441E (pt) 2011-09-28
EP1493441B1 (en) 2011-08-31
JP2011068692A (ja) 2011-04-07
CA2481916C (en) 2013-02-26
EP1493441A1 (en) 2005-01-05
DK1493441T3 (da) 2011-10-17
JPWO2003084537A1 (ja) 2005-08-11
US20090156652A1 (en) 2009-06-18
KR20130101162A (ko) 2013-09-12
KR20050002925A (ko) 2005-01-10
CY1112057T1 (el) 2015-11-04
EP1493441A4 (en) 2007-10-17
ATE522214T1 (de) 2011-09-15
US20200375954A1 (en) 2020-12-03
KR20110010837A (ko) 2011-02-07
JP5360075B2 (ja) 2013-12-04
WO2003084537A1 (en) 2003-10-16
US20150141475A1 (en) 2015-05-21
CA2481916A1 (en) 2003-10-16
EP2301540A1 (en) 2011-03-30
CN1646123A (zh) 2005-07-27
AU2003236326A1 (en) 2003-10-20
SI1493441T1 (sl) 2011-12-30
CN102125551B (zh) 2015-07-22
CN102125551A (zh) 2011-07-20
US20050176788A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US20200375954A1 (en) Therapeutic agent for food competence disorder in stomach
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
ES2251095T3 (es) Agentes terapeuticos para complicaciones diabeticas.
WO2013149148A2 (en) Dosage forms of halofuginone and methods of use
US8748489B2 (en) Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent
ES2496190T3 (es) Agente profiláctico y/o terapéutico para trastornos gastrointestinales funcionales
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
TW201601715A (zh) 膀胱‧尿道協同失調改善劑
JP7342259B2 (ja) 過敏性腸症候群の予防又は治療のための医薬的組み合わせ
ES2376023T3 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
KR100869759B1 (ko) 변비형 ｉｂｓ 예방제/치료제
KR102900174B1 (ko) 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR20210029739A (ko) 피렌페론 화합물을 유효성분으로 포함하는 취약 x 증후군 및 관련 발달 장애치료용 조성물
TW202448422A (zh) 末梢神經障礙之治療或預防用的醫藥
JP2021172639A (ja) 医薬組成物
US20240216284A1 (en) Alpelisib formulation
JPS62174020A (ja) 急性胃炎治療剤